The Role of miR-1183: A Potential Suppressor in Hepatocellular Carcinoma via Regulating Splicing Factor SRSF1
Zhilu Yao,Ning Liu,Hui Lin,Yingqun Zhou
DOI: https://doi.org/10.2147/JHC.S408542
2023-07-22
Journal of Hepatocellular Carcinoma
Abstract:Zhilu Yao, 1, 2, &ast Ning Liu, 3, &ast Hui Lin, 1 Yingqun Zhou 2, 4 1 Department of Gastroenterology, Jingan District Zhabei Central Hospital, Shanghai, 200072, People's Republic of China; 2 Clinical Medical College of Shanghai Tenth People's Hospital, Nanjing Medical University, Nanjing, Jiangsu, 211166, People's Republic of China; 3 Department of Gastroenterology, Changzhou Maternal and Child Health Hospital, Changzhou, 213004, People's Republic of China; 4 Department of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yingqun Zhou; Hui Lin, Email ; Purpose: Hepatocellular carcinoma (HCC) is a severe global health problem, causing many deaths of patients all over the world. Serine and arginine-rich splicing factor 1 (SRSF1) functions as an important oncogenic role in tumorigenesis and progression in HCC. Therefore, therapies targeting SRSF1 may provide promising therapeutic approaches. MiRNAs are virtually involved at the post-transcriptional level and bind to 3' untranslated region (3'-UTR) of their target messenger RNA (mRNA) to suppress expression. Methods: Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used to detect the expression of SRSF1 and miR-1183 in HCC cell lines. CCK8 assay, colony formation assay and wound healing assay were used to detect the function of miR-1183 in HCC cell lines in vitro. Luciferase reporter assay and Western blot were applied to detect the regulation of particular molecules. Xenograft tumor assay was used to detect the function of miR-1183 in HCC cell lines in vivo. Immunohistochemistry (IHC) was used to detect the expression of SRSF1 in HCC tissues and Xenograft tumors. Results: In this study, we identified that miR-1183 was downregulated in HCC cell lines. Functional assays indicated that miR-1183-upregulation cells show weakened proliferation ability and migration ability in vitro and inhibit subcutaneous tumor formation in vivo. With respect to the underlying mechanism, we found that miR-1183 function as a tumor suppressor by specifically binding to SRSF1. Conclusion: This study is the first to demonstrate that miR-1183 function as an important tumor-suppressing role by binding to the 3'-UTR of SRSF1 mRNA and suppressing its protein level in HCC cells in vitro and in vivo. Further, miR-1183 may be a potential target in the prognosis and treatment of HCC. Keywords: SRSF1, miR-1183, HCC, proliferation, migration Hepatocellular carcinoma (HCC) is a severe global health problem, causing many deaths of patients all over the world. 1 Despite significant advances in surgical operations and medicine treatment, there are still many HCC patients diagnosed at advanced stages by the time of initial diagnosis. 2 The prognosis for unresectable HCC remains unsatisfactory. Therefore, it is urgent to deeply elucidate the potential molecular mechanism of HCC and identify promising novel targets for therapy. In recent years, studies have shown that abnormal regulation of alternative splicing (AS) is usually accompanied by the occurrence and development of tumors. 3 The serine/arginine (SR) splicing factor family consists of 12 members. SR protein can participate in RNA splicing, transcription, export, translation and degradation by the RNA recognition motifs (RRM) and an RS domain. 4,5 For example, SRSF6 functions as an oncogene in mediating colorectal cancer (CRC) progression through regulating ZO-1 aberrant splicing. 6 SRSF3 markedly promotes the proliferation and migration of CRC cells through upregulating its target gene DHCR24. 7 As a member of SR splicing factor family, splicing factor SRSF1 is upregulated in various types of cancer and its expression level is related to the occurrence, development and treatment response of multiple tumors. 8 SRSF1 could inhibit autophagy by regulating Bcl-x splicing in lung cancer. 9 In addition, SRSF1 exerts oncogenic roles in breast cancer by regulating the AS of PTPMT1. 10 Importantly, SRSF1 promotes tumor invasion and metastasis in HCC cells by interacting with the exon 3 of SRA1 pre-mRNA. 11 Furthermore, SRSF1 could bind to RECQL4 mRNA and enhance its stability, thereby promoting the progression of HCC. 12 Previous studies have shown the oncogenic role of SRSF1 in HCC. Therefore, therapies targeting SRSF1 may provide promising therapeutic approaches. Many previous studies have demonstrated the roles of deregulated miRNAs in multi -Abstract Truncated-
oncology